Tempus AI Rally Puts Spotlight on AI for Science Peer Deshi Technology

A recent surge in the stock of U.S.-based Tempus AI (NASDAQ:TEM) is focusing investor attention on the burgeoning 'AI for Science' (AI4S) sector, prompting a re-evaluation of companies like Hong Kong-listed Deshi Technology Inc. (HKG:02526) that are building similar data-driven platforms for medical research.

Market Catalyst from Tempus AI

The AI and life sciences sector saw significant investor interest on September 17, when shares of Tempus AI surged as much as 15.93% to an intraday high of $81.12. The move was part of a broader trend, with other Hong Kong-listed AI healthcare firms like Jentai Biotech (07666) and Insilico Medicine (03696) climbing 12.70% and 6.86%, respectively, on the same day, while Deshi Technology posted a modest gain of 0.39%.

Tempus's valuation is underpinned by its success in commercializing large-scale medical data. In its second quarter of 2026, the company's Data and Applications business revenue reached $93.2 million, a 28% year-over-year increase. During a Morgan Stanley conference on September 15, Tempus management highlighted its competitive moat, built on hospital partnerships, data pipelines, and the ability to link clinical records with molecular and imaging data. The company also announced plans to build a platform of 100,000 whole genomes linked to clinical information, signaling a market shift toward valuing the systems that produce high-quality data and models, not just individual AI products.

Deshi's AI4S Platform and Strategy

Deshi Technology is positioning itself within the AI4S framework, which integrates machine learning with scientific data and expert knowledge to accelerate research. The company's strategy centers on its iMedLoop platform, launched on July 4, 2026. This system is designed to create a closed-loop workflow for medical AI development, encompassing data ingestion, professional annotation, quality control, model training, and application feedback.

Ad

The platform aims to convert the tacit knowledge of medical experts into structured, reusable assets for AI development. For instance, its iMedStudio tool allows for AI-assisted pre-annotation, which is then reviewed and corrected by specialists. According to its website on September 17, the iMedLoop platform has processed approximately:

• 29.015 million annotated samples
• 466.8 TB of imaging data
• 222 active tasks
• 3,172 certified experts

Financials and Path Forward

Deshi already has a growing commercial foundation for its AI services. In the first half of 2026, the company's model services revenue was CNY 94.541 million (approx. $13.2 million), a year-over-year increase of 101.1%, accounting for 86.9% of its total revenue. This growth occurred before the launch of the iMedLoop platform.

For investors, the key questions are whether the platform can drive further revenue growth, reduce development and delivery costs through standardization, and expand across multiple medical specialties. The market's positive reaction to Tempus suggests that companies capable of turning high-quality medical data into commercially viable workflows can command premium valuations. Deshi's future performance will likely be judged on its ability to demonstrate tangible results in model efficacy, new partnerships, and cost efficiency generated by its new platform.